Omburtamab
CNS/Leptomeningeal Metastasis from Neuroblastoma
PivotalActive
Key Facts
Indication
CNS/Leptomeningeal Metastasis from Neuroblastoma
Phase
Pivotal
Status
Active
Company
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, founded in 2015 and headquartered in New York, is a commercial-stage biotech company specializing in antibody-based oncology treatments. Its lead asset, DANYELZA, is an FDA-approved therapy for relapsed/refractory high-risk neuroblastoma, representing a significant advancement for a rare pediatric cancer. The company is now part of SERB Pharmaceuticals, which provides strategic and financial backing for its pipeline development. Y-mAbs continues to leverage its expertise in radioimmunotherapy and antibody engineering to address unmet needs in solid tumors.
View full company profile